Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $185.20.

Several equities analysts have issued reports on the company. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Finally, StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a report on Thursday.

Repligen Price Performance

Repligen stock opened at $144.46 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business has a 50 day simple moving average of $144.18 and a 200-day simple moving average of $141.67. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The stock has a market capitalization of $8.09 billion, a PE ratio of -390.42, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.23 EPS. Equities analysts predict that Repligen will post 1.54 earnings per share for the current year.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank lifted its holdings in shares of Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 75 shares during the period. DekaBank Deutsche Girozentrale raised its stake in Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 89 shares during the period. MML Investors Services LLC boosted its holdings in shares of Repligen by 2.7% in the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares during the last quarter. Ballentine Partners LLC grew its stake in shares of Repligen by 6.2% during the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 105 shares during the period. Finally, CWM LLC grew its stake in shares of Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 114 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.